# 以下为纯文本简介，不带文件格式；详细内容请下载文档查看；
Biopharma and Medtech
Deals and Funding
2022 Annual Outlook
Powered by
Executive summary
Life sciences still going strong entering 2022 2021 was another banner year for dealmaking in the life sciences
sector. Biopharma therapeutics and discovery platform companies
led the way in licensing and venture capital attraction—while
medtech activity remained well above its pre-pandemic levels.
With many bio-tech stocks trading off their 52-week highs, it
will be interesting to see if the pre-clinical, early-stage IPOs
continue in 2022.
Parameters
Biopharma companies are defined as firms developing therapeutics
and technology platforms engaged in drug discovery, clinical R&D
and commercialization. Medtech companies are defined as firms
developing medical devices, diagnostics, digital health therapeutics
and research tools. Therapy areas, development stages and
modalities are segmented per the DealForma database.
At J.P. Morgan, we have a team of bankers and specialists
dedicated to the life sciences and healthcare sectors. We believe
deeply in the pivotal contributions these clients add to society,
shareholders and employees alike.
Here are a few of the highlights o。。。以下略